FDA issues warning letter over Cymbalta physician promo

Share this article:

The FDA has issued Eli Lilly a warning letter over effectiveness claims the company made in a 2005 promotional mailer to physicians for its blockbuster antidepressant/nerve pain treatment Cymbalta.
 
In a letter posted to the FDA's Web site on Tuesday, the agency said Lilly's promotion intended to promote its indication as a treatment for diabetic nerve pain was “false and misleading” and omitted some of the most serious and important risk information associated with its use.

The agency asked that Lilly stop using the material or similar promotions.

A Lilly spokesman told The Indianapolis Star that the company is working with the FDA "to gain a greater understanding of their concerns."

The spokesman said Lilly will take action once it has "more clarity" on the agency's comments.

Launched in 2004, Cymbalta has become Lilly's fastest-growing drug, with global sales $1.3 billion in 2006.

Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...